Natixis
CRL icon

Natixis’s Charles River Laboratories CRL Stock Holding History

Natixis’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.4M Buy
+41,893
New +$11M 0.04% 292
2025
Q4 		– Sell
-14,010
Closed -$2.19M – 1158
2025
Q3 		$2.19M Buy
14,010
+7,058
+102% +$1.12M 0.01% 553
2025
Q2 		$1.05M Buy
6,952
+3,980
+134% +$531K ﹤0.01% 597
2025
Q1 		$444K Buy
+2,972
New +$498K ﹤0.01% 672
2024
Q4 		– Sell
-3,473
Closed -$684K – 1068
2024
Q3 		$684K Sell
3,473
-268
-7% -$55.7K ﹤0.01% 586
2024
Q2 		$773K Sell
3,741
-164
-4% -$37.2K ﹤0.01% 543
2024
Q1 		$1.06M Buy
+3,905
New +$933K 0.01% 520
2023
Q2 		– Sell
-4,722
Closed -$953K – 1041
2023
Q1 		$953K Buy
+4,722
New +$1.07M 0.01% 532
2022
Q4 		– Sell
-30,625
Closed -$6.03M – 1138
2022
Q3 		$6.03M Buy
30,625
+27,800
+984% +$6M 0.03% 370
2022
Q2 		$605K Sell
2,825
-42,789
-94% -$10.5M ﹤0.01% 912
2022
Q1 		$13M Buy
45,614
+30,439
+201% +$9.39M 0.05% 357
2021
Q4 		$5.72M Buy
15,175
+2,562
+20% +$995K 0.02% 522
2021
Q3 		$5.2M Buy
12,613
+6,633
+111% +$2.75M 0.02% 526
2021
Q2 		$2.21M Buy
+5,980
New +$2M 0.01% 507
2020
Q2 		– Sell
-66,200
Closed -$8.36M – 751
2020
Q1 		$8.36M Sell
66,200
-6,214
-9% -$932K 0.07% 211
2019
Q4 		$11M Sell
72,414
-35,450
-33% -$4.91M 0.07% 267
2019
Q3 		$14.3M Buy
107,864
+69,281
+180% +$9.29M 0.09% 200
2019
Q2 		$5.48M Sell
38,583
-105,076
-73% -$14.3M 0.04% 310
2019
Q1 		$20.6M Buy
143,659
+92,692
+182% +$12.2M 0.13% 164
2018
Q4 		$5.77M Sell
50,967
-34,721
-41% -$4.35M 0.05% 300
2018
Q3 		$11.5M Buy
85,688
+42,666
+99% +$5.27M 0.07% 257
2018
Q2 		$4.83M Buy
+43,022
New +$4.65M 0.03% 387
2017
Q4 		– Sell
-3,132
Closed -$338K – 901
2017
Q3 		$338K Sell
3,132
-46
-1% -$4.73K ﹤0.01% 849
2017
Q2 		$321K Buy
3,178
+95
+3% +$8.74K ﹤0.01% 624
2017
Q1 		$277K Buy
+3,083
New +$262K ﹤0.01% 742

Other funds holding CRL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Cooke & Bieler
Cooke & Bieler Philadelphia, Pennsylvania $6.36B AUM 0.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Van Berkom & Associates
Van Berkom & Associates Montreal, Quebec, Canada $2.81B AUM 6.02% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Natixis's CRL Position: Q3 2026 in Review

Natixis opened a new position in Charles River Laboratories (CRL) in Q3 2026: 41,893 shares worth $12.4M. The stake represents 0.04% of the portfolio and ranks #292 among its holdings. This is a return to the name: Natixis previously reported a position in CRL as recently as Q3 2025.

Natixis first reported a position in CRL in Q1 2017 and has held it in 25 quarters since. The position peaked at $20.6M in Q1 2019. 285 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Natixis held 41,893 shares of Charles River Laboratories worth $12.4M as of Q3 2026.
  • Charles River Laboratories was a new Natixis position in Q3 2026.
  • Charles River Laboratories made up 0.04% of Natixis's portfolio in Q3 2026, its #292 holding.
  • Natixis first reported a position in Charles River Laboratories in Q1 2017 and has held it in 25 quarters since.
  • Natixis's Charles River Laboratories position peaked at $20.6M in Q1 2019.
  • 285 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Natixis's 13F filing for Q3 2026, filed 6 Nov 2026.